Pittenger & Anderson Inc. Purchases 8,669 Shares of Edwards Lifesciences Corporation $EW

Pittenger & Anderson Inc. grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 49.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,186 shares of the medical research company’s stock after purchasing an additional 8,669 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Edwards Lifesciences were worth $2,097,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares during the period. Assenagon Asset Management S.A. lifted its stake in Edwards Lifesciences by 39.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after purchasing an additional 648,870 shares during the last quarter. Central Pacific Bank Trust Division purchased a new stake in Edwards Lifesciences during the fourth quarter valued at about $775,000. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences during the fourth quarter valued at about $2,984,000. Finally, Norges Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $803,686,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 1.0%

Shares of Edwards Lifesciences stock traded up $0.89 during trading on Friday, reaching $92.22. 3,381,397 shares of the stock were exchanged, compared to its average volume of 4,354,287. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock’s fifty day moving average is $86.73 and its 200 day moving average is $83.87. The firm has a market cap of $53.10 billion, a price-to-earnings ratio of 49.05, a price-to-earnings-growth ratio of 2.31 and a beta of 0.86. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent research reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. Evercore restated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $97.09.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.